Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review

Research output: Contribution to journalArticlepeer-review

Abstract

Alopecia areata (AA) is an immune-mediated hair loss disease for which targeted immune treatments including Janus kinase (JAK) inhibitors, for example, tofacitinib, are emerging. More literature is needed on the safety and efficacy of JAK inhibitors, and treatment has the potential to be cost prohibitive. This study was conducted to measure safety and efficacy outcomes of off-label use of tofacitinib in AA. A secondary outcome was analysis of payment methods. We reviewed 35 AA patients treated with tofacitinib in a specialty hair disease clinic between January 2013 and July 2019 for outcomes, adverse events, and feasibility of treatment. No serious adverse events were experienced. 83.9% of patients experienced clinically significant scalp regrowth, and 32.3% experienced near total/total regrowth. Though this study was confined to retrospective analysis, the results showed that tofacitinib was safe, effective, and practical for this cohort of 35 AA patients.

Original languageEnglish (US)
Article numbere15310
JournalDermatologic therapy
Volume35
Issue number4
DOIs
StatePublished - Apr 2022

Bibliographical note

Funding Information:
This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. IRB approval status: Reviewed and approved by University of Minnesota IRB; approval STUDY00004088. Data can be made available by the authors upon reasonable request.

Funding Information:
This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. IRB approval status: Reviewed and approved by University of Minnesota IRB; approval STUDY00004088. Data can be made available by the authors upon reasonable request.

Publisher Copyright:
© 2022 Wiley Periodicals LLC.

Keywords

  • Alopecia/chemically induced
  • Alopecia Areata/chemically induced
  • Humans
  • Piperidines
  • Pyrimidines/adverse effects
  • Pyrroles/adverse effects
  • Retrospective Studies

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review'. Together they form a unique fingerprint.

Cite this